Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
AstraZeneca will sell discounted drugs on TrumpRx, aligning with the MFN executive order to avoid potential tariffs. The agreement includes a $50 billion investment in US drug manufacturing and R&D, ...
PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
A rare clotting disorder puzzled doctors during the COVID vaccine rollout. New research reveals the unlikely chain of events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results